Not exactly, but it can be a helpful addition. Your doctor can advise if Trucheck™ Intelli is a suitable option alongside your usual cancer screenings.
Yes, Trucheck™ Intelli requires a prescription from your doctor. They will guide you on whether it is the right choice for you.
You can request the test through your healthcare provider or we can help connect you with one to discuss it directly.
We can inform your healthcare provider about Trucheck™ Intelli or connect you with our clinical partners to discuss it further.
No, in this case, you should seek immediate medical advice.
Trucheck™ Intelli is helpful for individuals who have no symptoms but are at higher cancer risk due to factors like family history or age. Talk to your doctor to find out if Trucheck™ Intelli is suitable for you.
Trucheck™ Intelli screens for over 70 types of solid Tumour.
Trucheck™ Intelli is effective when taken annually, so we recommend having the test once a year.
Trublood™ uses an advanced technique called immunocytochemistry (ICC) staining to detect Circulating Tumour Cells(CTCs) in your blood. These are cancer cells that may have broken away from the main tumour and entered your bloodstream, potentially helping cancer spread. Trublood™ not only detects the presence of these cells but also identifies different types of cancers by looking at the specific molecular or protein markers. This helps provide valuable insights into your cancer's characteristics and possible progression.
Unlike standard CTC tests that only count the cells, Trublood™ captures, expands, and thoroughly examines the CTCs to identify distinct variations within the cancer, offering a detailed understanding of its characteristics.
Trublood™ detects cancers called carcinomas, which are the types that start in the lining of organs and body surfaces, like the skin, lungs, and colon. However, it doesn't detect blood cancers like leukaemia or lymphoma.
Yes, Trublood™ can often differentiate between cancers originating in glandular cells (like adenocarcinoma) and those in the skin or lung linings (like squamous cell carcinoma).
Trublood™ can detect common cancers like adenocarcinoma, squamous cell carcinoma, and hormone-related (neuroendocrine) tumour, but it might miss some rare types.
Trublood™ identifies the type of epithelial cancer but does not provide information on the tumours grade or aggressiveness.
Trublood™ is designed for detecting carcinoma in patients with cancer symptoms or signs, not for ongoing monitoring by counting CTCs.
The Trublood™ validation study does not include cancers that haven't spread but research indicates that CTCs may be detectable in some cases.
Yes, Trublood™ has been tested in both early-stage and advanced cancers, with an overall accuracy of 94.6%.
Trublood™ isn't a general screening test. It is designed to detect cancer in patients who already have specific symptoms or signs related to a particular organ-related cancer.
Trublood™ is validated for cases with a specific organ suspicion, not for non-specific symptoms like weight loss without a particular organ focus.
A blood sample is taken from a vein, like routine blood tests, but with specific storage and transport requirements.
It is transported in temperature-controlled packaging.
Consult with your doctor for further evaluations.
Trublood™ is a highly specific test, but a biopsy may still be recommended based on your doctor's advice.
You can repeat the test in a month and consult with your doctor.
Yes, doctors use Trublood™ test for detection of organ-specific cancer cases, especially if a biopsy is challenging.
No, Trublood™ test is validated for use only in adults, 18 years and older.
Trublood™ is a non-invasive blood test that can detect the presence of cancer and its type without requiring a tissue biopsy.
Trublood™ tests cannot detect certain cancer types, like blood cancers or some rare carcinomas.
Your doctor may consider Trublood™ test results but will factor in other test results as well.
No, Trublood™ test is not designed to detect blood cancers.
Exacta™ goes beyond mutation detection by integrating genomic, transcriptomic, and functional analysis. It not only identifies alterations but also evaluates tumour behaviour and actual drug response to guide treatment selection.
Exacta™ is particularly valuable in complex scenarios such as treatment failure, relapse, aggressive disease, or when standard options are limited or unclear.
Yes. Exacta™ is specifically designed to uncover hidden resistance mechanisms and identify alternative treatment strategies, even in heavily pre-treated or refractory cancers.
Yes. Unlike conventional tests, Exacta™ includes functional chemosensitivity testing on live tumour cells to help identify which chemotherapy drugs are more likely to be effective.
No. While highly valuable in advanced settings, Exacta™ can also support treatment planning in newly diagnosed aggressive or hard-to-treat cancers.
Exacta™ can be performed using tumour tissue, blood samples, or a combination of both, depending on the clinical scenario and sample availability.
By analysing both genetic alterations and pathway activity, Exacta™ identifies therapies that are most likely to be effective based on how the tumour is functioning—not just which mutations are present.
Yes. Exacta™ evaluates relevant biomarkers such as TMB, MSI, and other immune-related indicators to support immunotherapy decision-making.
Results are delivered as a clear, structured report with prioritised treatment options, supporting evidence, and insights to help guide personalised clinical decisions.
No two cancers are exactly alike. Comprehensive Genomic Profiling (CGP) is a laboratory test that analyzes a tumour’s genetic code to identify specific “driver” mutations responsible for cancer growth.
Traditional treatments like chemotherapy are often one-size-fits-all. CGP helps clinicians identify targeted therapies-treatments designed to specifically act on cancer-driving mutations—often enabling more precise and effective care with fewer side effects.
No extra procedures: Uses tissue already collected during biopsy or surgery, avoiding additional invasive steps
Fast answers: Results are typically available within approximately one week, enabling timely clinical decisions
A clear path forward: Comprehensive, structured tumour mutation profiling to support the oncologist's next conversation
Celldx™ can be ordered by oncologists or healthcare providers through the designated test requisition process or by contacting our support team.
Celldx™ evaluates hundreds of genes in a single assay, enabling a broader and more clinically meaningful understanding of tumour biology and is suitable for molecular evaluation of solid tumours.
Celldx™ evaluates hundreds of genes in a single assay, enabling a broader and more clinically meaningful understanding of tumour biology compared to limited single-gene tests.
Results are provided in a simplified, clinically intuitive report that includes: Detected genomic variants classified by clinical significance level, ERBB2 amplification status, and ALK/RET/ROS1 fusion status.
Results are shared securely with the ordering clinician through designated reporting channels.
Chemoscale™ tests live cancer cells to find out which drugs or combinations are likely to work best for you. This way, it avoids the costly 'trial and error' method, helping you and your doctor choose the most effective treatments based on real results.
Chemo-Scale™ is helpful for all patients with solid tumours, especially those who are starting chemotherapy for the first time or dealing with cancer that has come back.
Not all chemotherapy drugs work the same for everyone. Chemoscale™ shows which treatments are likely to be effective before starting, thus saving time and resources.
While most molecular tests focus on targeted therapies, Chemoscale™ specifically analyses how a patient's cancer cells respond to chemotherapy drugs, allowing for accurate treatment recommendations.
Chemo-Scale™ is suitable for most cancer patients for whom chemotherapy is a treatment option.
Results are available within 8-10 working days after the sample is received.
It detects circulating tumor cells (CTCs) and tumor-derived DNA and RNA in the bloodstream to assess cancer activity in real time.
It identifies molecular changes in the blood that may appear earlier than changes visible on imaging, enabling more proactive treatment decisions.
No. It complements existing diagnostic methods by providing continuous molecular monitoring between scans or when tissue is unavailable.
It is applicable across all solid tumors, as it relies on circulating tumor-derived signals rather than tumor location.
Testing can be done at multiple timepoints—baseline, during treatment, and follow-up—based on clinical need.
The report includes cancer activity status, treatment response trends, emerging resistance signals, and actionable molecular changes.
It can detect molecular changes weeks to months earlier than conventional methods, depending on tumor biology and burden.
Yes. It is a fully blood-based test and does not require tumor tissue.
No. Results should be interpreted alongside clinical and imaging findings, as very low disease levels may be below detection limits.